Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Nautilus Biotechnology, Inc. - Common Stock (NQ:NAUT)

2.175 +0.125 (+6.10%)
Streaming Delayed Price Updated: 2:31 PM EST, Jan 21, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Nautilus Biotechnology, Inc. - Common Stock

< Previous 1 2 3 4 5 Next >
News headline image
Nautilus Biotechnology Reports Third Quarter 2024 Financial Results
From Nautilus Biotechnology Inc.
Via GlobeNewswire
News headline image
Nautilus Biotechnology to Announce Third Quarter 2024 Financial Results on October 29, 2024
From Nautilus Biotechnology Inc.
Via GlobeNewswire
News headline image
Nautilus Biotechnology Appoints Mass Spectrometry Leader Ken Suzuki as Chief Marketing Officer
Industry veteran brings multidisciplinary expertise leading Mass Spectrometry division at Agilent Technologies to a company building a platform to power next-generation proteomics 
From Nautilus Biotechnology Inc.
Via GlobeNewswire
News headline image
Nautilus Biotechnology to Participate in the Morgan Stanley 22nd Annual Global Healthcare Conference
From Nautilus Biotechnology Inc.
Via GlobeNewswire
News headline image
NAUT Stock Earnings: Nautilus Biotechnology Beats EPS for Q2 2024 ↗
NAUT stock results show that Nautilus Biotechnology beat analyst estimates for earnings per share the second quarter of 2024. 
Via InvestorPlace
News headline image
Nautilus Biotechnology Reports Second Quarter 2024 Financial Results
From Nautilus Biotechnology Inc.
Via GlobeNewswire
News headline image
Nautilus Biotechnology to Announce Second Quarter 2024 Financial Results on July 30, 2024
From Nautilus Biotechnology Inc.
Via GlobeNewswire
News headline image
Nautilus Biotechnology to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference
From Nautilus Biotechnology Inc.
Via GlobeNewswire
News headline image
NAUT Stock Earnings: Nautilus Biotechnology Beats EPS for Q1 2024 ↗
NAUT stock results show that Nautilus Biotechnology beat analyst estimates for earnings per share the first quarter of 2024. 
Via InvestorPlace
News headline image
Nautilus Biotechnology Reports First Quarter 2024 Financial Results
From Nautilus Biotechnology Inc.
Via GlobeNewswire
News headline image
Nautilus Biotechnology to Announce First Quarter 2024 Financial Results on April 30, 2024
From Nautilus Biotechnology Inc.
Via GlobeNewswire
News headline image
12 Health Care Stocks Moving In Friday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Nautilus Biotechnology Reports Fourth Quarter and Fiscal Year 2023 Financial Results
From Nautilus Biotechnology Inc.
Via GlobeNewswire
News headline image
Nautilus Biotechnology to Participate in the TD Cowen 44ᵗʰ Annual Healthcare Conference
From Nautilus Biotechnology Inc.
Via GlobeNewswire
News headline image
Nautilus Biotechnology to Announce Fourth Quarter and Full Year 2023 Financial Results on February 28, 2024
From Nautilus Biotechnology Inc.
Via GlobeNewswire
News headline image
Nautilus Biotechnology Co-founder and Chief Scientist Parag Mallick, Ph.D., Honored with US HUPO Computational Proteomics Award
Society award recognizes Dr. Mallick’s decades of innovative leadership and science advancing the field of computational proteomics 
From Nautilus Biotechnology Inc.
Via GlobeNewswire
News headline image
12 Health Care Stocks Moving In Friday's After-Market Session ↗
 
Via Benzinga
News headline image
Nautilus Biotechnology Appoints Martin Huber, Ph.D., as Vice President of Biochemistry and Flow Cell Development
Former Quantapore founder and CEO brings 20 years of proteomics and genomics industry experience to company developing a platform for comprehensively quantifying the proteome 
From Nautilus Biotechnology Inc.
Via GlobeNewswire
News headline image
Nautilus Biotechnology Reports Third Quarter 2023 Financial Results
From Nautilus Biotechnology Inc.
Via GlobeNewswire
News headline image
Nautilus Biotechnology to Announce Third Quarter Financial Results on October 31, 2023
From Nautilus Biotechnology Inc.
Via GlobeNewswire
News headline image
12 Health Care Stocks Moving In Thursday's After-Market Session ↗
 
Via Benzinga
News headline image
Williams-Sonoma, ESS Tech And Other Big Stocks Moving Higher On Monday ↗
U.S. stocks traded lower, with the Dow Jones falling around 100 points on Monday. Here are some big stocks recording gains in today’s session. 
Via Benzinga
Topics Stocks
News headline image
Nautilus Biotechnology to Participate in Upcoming September Investor Conferences
From Nautilus Biotechnology Inc.
Via GlobeNewswire
News headline image
Farfetch, Faraday Future Intelligent Electric, VinFast, And Other Stocks Moving Lower On Friday ↗
U.S. stocks traded down this morning, with the Nasdaq Composite falling more than 101 points on Friday. Here are some big stocks recording gains in today’s session. 
Via Benzinga
Topics Stocks
News headline image
US Stocks Sink; Deere Shares Fall Despite Earnings Beat ↗
U.S. stocks traded down this morning with the Nasdaq Composite falling more than 101 points on Friday. The Dow traded down 0.23% to 34,396.96 while the NASDAQ fell 0.91% to 13,196.22. The S&P 500 also... 
Via Benzinga
Topics Stocks
News headline image
Nautilus Biotechnology to Participate in Upcoming August Investor Conferences
From Nautilus Biotechnology Inc.
Via GlobeNewswire
News headline image
Nautilus Biotechnology Reports Second Quarter 2023 Financial Results
From Nautilus Biotechnology Inc.
Via GlobeNewswire
News headline image
Nautilus Biotechnology to Announce Second Quarter Financial Results on August 2, 2023
From Nautilus Biotechnology Inc.
Via GlobeNewswire
News headline image
12 Health Care Stocks Moving In Thursday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Why Avid Bioservices Shares Are Trading Lower By Over 14%? Here Are Other Stocks Moving In Thursday's Mid-Day Session ↗
Gainers Aeglea BioTherapeutics, Inc. (NASDAQ: AGLE) shares climbed 422% to $0.5572 after the company announced acquisition of Spyre Therapeutics and concurrent oversubscribed $210 million private... 
Via Benzinga
< Previous 1 2 3 4 5 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.